GlassScriptPhysician profile
Paul J Palisano
NPI 1861408858
$4,025.12
in general payments reported to CMS, 2019-2025
32 companies · $824 in 2025
The $824 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $132 · 2021: $232 · 2022: $946 · 2023: $1,104 · 2024: $668 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473 · Entertainment: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.69 |
| Entertainment | $123.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,115.97 | 2022-2025 | Acthar |
| Alcon Vision LLC | $520.14 | 2022-2025 | Total30, Precision 1, Dailies Total1 |
| Abbvie INC. | $518.93 | 2022-2025 | |
| Dompe US, INC. | $225.34 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $200.63 | 2020-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.25 | 2020-2021 | |
| Biotissue Holdings INC. | $157.35 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $139.78 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Optos, INC. | $123.00 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Maculogix, INC. | $76.35 | 2019 | |
| Bausch & Lomb Americas INC. | $75.10 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Oyster Point Pharma, INC. | $69.86 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $67.96 | 2024-2025 | Vevye, Iheezo |
| Rxsight INC | $65.13 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $57.87 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $44.73 | 2023-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $44.23 | 2020 | |
| Carl Zeiss Meditec, INC. | $42.88 | 2019 | |
| Astellas Pharma US INC | $33.60 | 2024 | Izervay |
| New World Medical,INC. | $30.38 | 2023 | |
| Eyepoint US, INC. | $28.66 | 2021 | |
| Aerie Pharmaceuticals, INC. | $26.46 | 2020-2021 | |
| Horizon Therapeutics Plc | $20.70 | 2023 | Tepezza |
| Sight Sciences, INC. | $20.66 | 2023 | Tearcare System |
| Glaukos Corporation | $19.89 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Omeros Corporation | $19.86 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.83 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $18.94 | 2025 | Syfovre |
| Lkc Technologies, INC. | $18.61 | 2025 | |
| Amgen INC. | $17.84 | 2025 | Tepezza |
| Allergan, INC. | $14.92 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Palisano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.